These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2863716)

  • 1. Disappearance of spironolactone-induced gynaecomastia during treatment with potassium canrenoate.
    Dupont A
    Lancet; 1985 Sep; 2(8457):731. PubMed ID: 2863716
    [No Abstract]   [Full Text] [Related]  

  • 2. Gynaecomastia after spironolactone and potassium canrenoate.
    Bellati G; Idéo G
    Lancet; 1986 Mar; 1(8481):626. PubMed ID: 2869341
    [No Abstract]   [Full Text] [Related]  

  • 3. Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy.
    Andriulli A; Arrigoni A; Gindro T; Karbowiak I; Buzzetti G; Armanini D
    Digestion; 1989; 44(3):155-62. PubMed ID: 2697627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphocyte function tests in cirrhotic patients under treatment with spironolactone and potassium canrenoate.
    Cuppone R; Del Vecchio S; Zanninelli G; Delle Monache M; Ulissi A; Tavanti A; Angeloni A; Ricci GL
    J Int Med Res; 1988; 16(6):436-42. PubMed ID: 3266156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Controlled study of the effect of long-term administration of canrenoate potassium in cirrhotic ascites].
    Traina M; Vizzini GB
    Minerva Med; 1986 Jan; 77(3-4):87-91. PubMed ID: 3511409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative clinical study of spironolactone and potassium canrenoate. A randomized evaluation with double cross-over.
    Emili M; Cuppone R; Ricci GL
    Arzneimittelforschung; 1988 Oct; 38(10):1492-5. PubMed ID: 3058132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical experience in the use of Osyrol 100 and Osyrol for injection (author's transl)].
    Gorbach HC; Bräuninger HJ
    MMW Munch Med Wochenschr; 1975 Sep; 117(37):1483-6. PubMed ID: 810673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiarrhythmic activity of potassium canrenoate in man.
    Yeh BK; Chiang BN; Sung PK
    Am Heart J; 1976 Sep; 92(3):308-14. PubMed ID: 949026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spontaneous resolution of idiopathic aldosteronism after long-term treatment with potassium canrenoate.
    Armanini D; Fiore C; Pellati D
    Hypertension; 2007 Oct; 50(4):e69-70. PubMed ID: 17709652
    [No Abstract]   [Full Text] [Related]  

  • 10. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
    Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
    Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spironolactone and potassium canrenoate in normal man.
    Ramsay L; Shelton J; Harrison I; Tidd M; Asbury M
    Clin Pharmacol Ther; 1976 Aug; 20(2):167-77. PubMed ID: 780038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spironolactone and potassium canrenoate metabolism.
    Gardiner P
    Lancet; 1985 Dec 21-28; 2(8469-70):1432. PubMed ID: 2867429
    [No Abstract]   [Full Text] [Related]  

  • 13. The use of diuretics in preventing ascites recurrence.
    Arrigoni A; Andriulli A; Gindro T; Verme G
    Br J Clin Pract; 1988 Mar; 42(3):116-20. PubMed ID: 3207572
    [No Abstract]   [Full Text] [Related]  

  • 14. Spironolactone and canrenoate-K: relative potency at steady state.
    Ramsay L; Asbury M; Shelton J; Harrison I
    Clin Pharmacol Ther; 1977 May; 21(5):602-9. PubMed ID: 858213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of spironolactone and K-canrenoate in ascitic cirrhosis. Double-blind study].
    Tempini S; Bellati G; Ideo G
    Minerva Dietol Gastroenterol; 1984; 30(3):255-61. PubMed ID: 6504374
    [No Abstract]   [Full Text] [Related]  

  • 16. A study of potassium canrenoate on the raised intracranial pressure.
    Node Y; Yajima K; Nakazawa S
    Nihon Ika Daigaku Zasshi; 1984 Apr; 51(2):264-5. PubMed ID: 6736215
    [No Abstract]   [Full Text] [Related]  

  • 17. [Use of the aldosterone antagonist, canrenoate potassium for treating chronic circulatory insufficiency].
    Sidorenko BA; Kudisov IuM; Rossel's AN; Razumova ET
    Kardiologiia; 1979 Mar; 19(3):41-6. PubMed ID: 372667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New clinical application of spironolactone].
    Fukuchi S
    Nihon Rinsho; 1974 Nov; 32(11):3326-32. PubMed ID: 4615183
    [No Abstract]   [Full Text] [Related]  

  • 19. [Sexual side-effects of spironolactones. Possible mechanisms of their anti-androgen action].
    Corvol P; Mahoudeau JA; Valcke JC; Ménard J; Bricaire H
    Nouv Presse Med; 1976 Mar; 5(11):691-4. PubMed ID: 177946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vivo metabolites of spironolactone and potassium canrenoate: determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay.
    Armanini D; Karbowiak I; Goi A; Mantero F; Funder JW
    Clin Endocrinol (Oxf); 1985 Oct; 23(4):341-7. PubMed ID: 4064345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.